Medicine is rapidly evolving from statistical, evidence-based approaches to predictive, genotype-directed care, driven by ...

BGI Group, one of the country's leading gene sequencing firms, is stepping up efforts to turn its life-science research and ...

The concept of biological age, distinct from chronological age, is gaining public traction, though often misinterpreted.

Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable. Read more on NTRA stock here.

For a child diagnosed with neuroblastoma—the most common infant cancer, occurring when early nerve cells grow out of ...

We look at power, speed, calories, recovery, fuelling and more to compare a Tour de France rider's efforts to those of an ...

A quantum-inspired AI approach can analyze millions of molecular features from small datasets, improving predictions, ...

Introduction Efficient preventive management of acute exacerbation of chronic obstructive pulmonary disease (COPD) is ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology ...

Cancer is one of the leading causes of death and disability, affecting millions of working-age adults and their families each ...

As patients are divided into ever more narrowly defined subgroups, the number of individuals available for research shrinks dramatically. While this approach improves personalization, it also creates ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation ...